{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:53:42Z","timestamp":1759010022687},"reference-count":37,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The global polio eradication program recommends the use of massive vaccination campaigns with live vaccine through National Immunization Days (NIDs) to displace the wild virus from the community. Immunodeficient patients may be indirectly infected and become chronic excretors and potential reservoirs of polioviruses, a concern for the posteradication era. This prospective study aimed to assess the risk of community-acquired infection of immunodeficient patients following NIDs, the dynamics of viral excretion and the genetic variation of excreted viruses. Sixteen children with various primary immunodeficiencies, who did not receive the vaccine during the campaign, were investigated. Stool samples were collected weekly, shortly after the NIDs, during at least 3 months, and were processed for viral isolation. Isolates were characterized by three intratypic differentiation methods and partial sequencing of the VP1\/2A region. Polioviruses were detected in 4 out of 16 patients (serotype 1 in 3 patients and serotype 3 in 1 patient). Sequencing revealed more than 99% homology with homotypic Sabin strains, suggesting recent infection. Duration of viral excretion ranged from 1 to 7 weeks. Nine out of eleven isolates from the three poliovirus serotype 1-infected patients disclosed a non-Sabin-like phenotype by enzyme-linked immunosorbent assay and had recurrent mutations within or close to the neutralizing antigenic sites. In summary, the risk of secondary infection in immunodeficient patients is within the range previously reported for the general population. Although none of the four infected patients developed prolonged viral excretion, particular viral variants were selected and may be of epidemiological significance.<\/jats:p>","DOI":"10.1128\/jcm.41.3.1203-1211.2003","type":"journal-article","created":{"date-parts":[[2003,3,6]],"date-time":"2003-03-06T19:07:00Z","timestamp":1046977620000},"page":"1203-1211","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":13,"title":["Community-Acquired Poliovirus Infection in Children with Primary Immunodeficiencies in Tunisia"],"prefix":"10.1128","volume":"41","author":[{"given":"Hinda","family":"Triki","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Virology, WHO Regional Reference Laboratory on Poliomyelitis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Ridha","family":"Barbouche","sequence":"additional","affiliation":[{"name":"Laboratory of Immunology, WHO Collaborating Center for Research and Training in Immunology, Institut Pasteur de Tunis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olfa","family":"Bahri","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Virology, WHO Regional Reference Laboratory on Poliomyelitis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Bejaoui","sequence":"additional","affiliation":[{"name":"Pediatrics Department, Bone Marrow Transplantation Center, Tunis, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koussay","family":"Dellagi","sequence":"additional","affiliation":[{"name":"Laboratory of Immunology, WHO Collaborating Center for Research and Training in Immunology, Institut Pasteur de Tunis"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/175.Supplement_1.S176"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.7.3689"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(91)90434-D"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-693X(97)88145-6"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1999.0003"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/30996"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530450029028"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.3.562-571.1995"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/361541a0"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Dowdle W. R. and M. E. Birmingham. 1997. The biologic principles of poliovirus eradication. J. Infect. Dis. 175 (Suppl. 1) : S286-S292.","DOI":"10.1093\/infdis\/175.Supplement_1.S286"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2000.17810.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.3.1099"},{"key":"e_1_3_2_14_2","first-page":"358","volume":"78","year":"2000","unstructured":"Fine, P. 2000. Gaps in our knowledge about transmission of vaccine-derived polioviruses. Bull. W. H. O.78:358-359.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/175.Supplement_1.S135"},{"key":"e_1_3_2_16_2","first-page":"199","volume":"55","year":"1983","unstructured":"Glikmann, G., M. Moynihan, I. Petersen, and B. F. Vestergaard. 1983. Intratypic differentiation of poliovirus strains by enzyme-linked immunosorbent assay (ELISA): poliovirus type1. Dev. Biol. Stand.55:199-208.","journal-title":"Dev. Biol. Stand."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.1981.tb00095.x"},{"key":"e_1_3_2_18_2","first-page":"1","volume":"118","year":"1999","unstructured":"IUIS Scientific Committee report. 1999. Primary immunodeficiency diseases. Clin. Exp. Immunol.118(Suppl. 1):1-28.","journal-title":"Clin. Exp. Immunol."},{"key":"e_1_3_2_19_2","first-page":"805","volume":"343","year":"2000","unstructured":"Jacob, J. T. 2000. The final stages of the global eradication of polio. N. Engl. J. Med.343:805-807.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.10.2893-2899.1998"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.9.1275"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.3.541"},{"key":"e_1_3_2_23_2","first-page":"72","volume":"310","year":"1971","unstructured":"MacCallum, F. O. 1971. Hypogammaglobulinemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinemia. Spec. Rep. Ser. Med. Res. Counc. (Great Britain)310:72-88.","journal-title":"Spec. Rep. Ser. Med. Res. Counc. (Great Britain)"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.7.3001-3010.2000"},{"key":"e_1_3_2_25_2","first-page":"221","volume":"72","year":"1994","unstructured":"Mas Lago, P., J. R. Bravo, J. K. Andrus, M. M. Comellas, M. A. Galindo, C. A. de Quadros, and E. Bell. 1994. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull. W. H. O.72:221-225.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-80-4-907"},{"key":"e_1_3_2_27_2","first-page":"381","volume":"4","year":"1987","unstructured":"Ochoa, E. G., and P. Mas Lago. 1987. Epidemiological surveillance and control of poliomyelitis in the republic of Cuba. J. Hyg. Epidemiol. Microbiol. Immunol.4:381-389.","journal-title":"J. Hyg. Epidemiol. Microbiol. Immunol."},{"key":"e_1_3_2_28_2","first-page":"1094","volume":"48","year":"2000","unstructured":"Pan American Health Organization. 2000. Outbreak of poliomyelitis\u2014Dominican Republic and Haiti: 2000-2001. Morb. Mortal. Wkly. Rep.48:1094-1103.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_29_2","first-page":"769","volume":"73","year":"1995","unstructured":"Richardson, G., R. W. Linkins, M. A. Eames, D. J. Wood, P. J. Campbell, E. Ankers, M. Deniel, A. Kabbaj, D. I. Magrath, P. D. Minor, and P. A. Patriarca. 1995. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes. Bull. W. H. O.73:769-777.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_30_2","unstructured":"Infect. Med. June:426-438. 1994"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(84)90084-6"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.10.2562-2566.1995"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890240410"},{"key":"e_1_3_2_34_2","first-page":"347","volume":"78","year":"2000","unstructured":"Wood, D. J., R. W. Sutter, and W. R. Dowdle. 2000. Stopping poliovirus vaccination after eradication: issues and challenges. Bull. W. H. O.78:347-357.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_35_2","unstructured":"World Health Assembly. 1988. Global eradication of polio by the year 2000. Resolutions and decisions. W.H.O. resolution WHA 41. World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_36_2","unstructured":"World Health Organization. 1992. Manual for the virological investigation of poliomyelitis. Geneva. W.H.O.\/EPI\/CDS\/POLIO\/90.1. World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_37_2","first-page":"41","volume":"50","year":"2001","unstructured":"World Health Organization Regional Reference Laboratory, Egypt. 2001. Circulation of a type2 vaccine-derived poliovirus. Egypt 1982-1993. Morb. Mortal. Wkly. Rep.50:41-51.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/128.6.802"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.41.3.1203-1211.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.41.3.1203-1211.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T02:04:28Z","timestamp":1646445868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.41.3.1203-1211.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1128\/JCM.41.3.1203-1211.2003"],"URL":"https:\/\/doi.org\/10.1128\/jcm.41.3.1203-1211.2003","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3]]},"assertion":[{"value":"2002-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-12-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}